Related Experiment Video
Updated: Sep 29, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
miR-93-5p suppresses ovarian cancer malignancy and negatively regulate CCND2 by binding to its 3'UTR region
Guotong Chen1, Yiwei Yan1,2, Xiaojv Qiu1,2
1Department of Obstetrics and Gynecology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Abstract:
Ovarian cancer is the most fatal gynecological cancer worldwide, yet the fundamental mechanism of malignancy acquisition in ovarian cancer remains unknown. miRNA has been implicated to a variety of diseases, including cancer initiation and progression. Cyclin-D2 (CCND2) is ubiquitously implicated in cancer uncontrol cell proliferation. Bioinformatic research revealed that CCND2 is a candidate gene for miR-93-5p with a binding site in its 3'UTR region in the current study. Using our ovarian cancer sample, we verified that miR-93-5p is negatively correlated with CCND2 mRNA and protein levels. Luciferase report assay revealed miR-93-5p inhibits CCND2 production through binding to the 3'UTR region. The expression of miR-93-5p in ovarian cancer patient samples was then determined, and a survival analysis was performed. Our findings showed that miR-93-5p is downregulated in ovarian cancer and is a favorable predictive factor in ovarian cancer patient. CCK8 assay, wound healing assay and flow cytometry-based cell cycle and apoptotic cell analyses were employed here. We found that miR-93-5p suppresses ovarian cancer cell proliferation and migration while enhances cell death. Our research certified that miR-93-5p reduces ovarian cancer malignancy by targeting CCND2.
Insights
MicroRNA-93-5p (miR-93-5p) is downregulated in ovarian cancer, suppressing tumor growth and migration by targeting Cyclin-D2 (CCND2). This finding identifies miR-93-5p as a potential biomarker for improved ovarian cancer patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer is a leading cause of cancer-related death globally, with mechanisms of malignancy poorly understood.
- MicroRNAs (miRNAs) play critical roles in cancer development and progression.
- Cyclin-D2 (CCND2) is frequently involved in uncontrolled cell proliferation in cancers.
Purpose of the Study:
- To investigate the role of miR-93-5p in ovarian cancer.
- To determine if miR-93-5p targets CCND2.
- To evaluate miR-93-5p as a prognostic biomarker in ovarian cancer.
Main Methods:
- Bioinformatic analysis to predict miRNA-target interactions.
- Ovarian cancer patient sample analysis for miRNA and mRNA expression.
- Luciferase reporter assays to confirm direct binding.
- Cell proliferation, migration, and apoptosis assays (CCK8, wound healing, flow cytometry).
Main Results:
- CCND2 was identified as a direct target of miR-93-5p, with inverse correlation in patient samples.
- miR-93-5p expression was significantly downregulated in ovarian cancer tissues.
- Downregulation of miR-93-5p correlated with poorer patient survival.
- miR-93-5p suppressed ovarian cancer cell proliferation and migration while promoting apoptosis.
Conclusions:
- miR-93-5p acts as a tumor suppressor in ovarian cancer by targeting CCND2.
- miR-93-5p is a potential diagnostic and prognostic biomarker for ovarian cancer.
- Targeting miR-93-5p may offer a therapeutic strategy for ovarian cancer.
Related Concept Videos
MicroRNAs
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Induced Pluripotent Stem Cells
Somatic...
Experimental RNAi
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

